Sabra Health Care REIT: The 5.8% Dividend Is Finally Earned

A price-target hike is a forecast about income, not income itself. So when Mizuho raised its target on Sabra Health Care REIT again this month — the latest of several Wall Street hikes in 2026 — the useful question is not whether the ticker lands at $23 or $25. It is whether the 5.8% yield is paid out of real, growing cash flow, or out of hope. That is the test Sabra has spent years failing — and the reason its dividend, at last, looks different.

The Mizuho move was not an outlier. Through 2024 Mizuho nudged its Sabra price target from $17 to $18, then to $20, keeping an Outperform rating and citing the company's AFFO growth as the reason. This month Sabra presented at Mizuho's second annual healthcare-REIT conference, and the firm raised its sights once more. The rest of the Street has joined the trip: Deutsche Bank moved its target to $25 in July, Bank of America holds a $25 target with a Buy, and Raymond James flipped from Underperform to Market Perform with a $23 target in early August. That is not momentum noise; it is a consensus forming around one idea — that the earnings engine finally supports the payout.

Read the latest quarter the way a ticker screen does, and those raises look perverse. Sabra reported a second-quarter net loss of $0.10 a share against a consensus that expected a gain. A headline loss and a run of analyst price-target hikes in the same season sounds like two different companies. And in a real sense, it is. The loss is mostly a $102.4 million non-cash loan-loss provision booked on the discounted payoff of its RCA mortgage — a cleanup of a legacy problem, one the company excludes from the numbers a REIT actually lives by.

Strip that out, and Q2 shows normalized FFO of $0.38 a share and normalized AFFO of $0.40 a share. The dividend costs $0.30 a quarter. That is roughly a 75% payout of adjusted funds from operations — coverage of about 1.3 times. REIT dividends are paid from AFFO, the cash a landlord truly keeps after maintenance and leasing costs; net income is the wrong lens because depreciation is a paper charge, not a cash check. That matters more than it sounds: Sabra cut its dividend during the pandemic, to $0.30 a quarter in 2020, and the yield has carried the aftertaste of that cut ever since. On the metric that funds the dividend, this is as well-covered a Sabra payout as investors have seen in a long time.

What changed is not just the coverage — it is the engine growing underneath it. Sabra has steadily shifted its portfolio toward managed senior housing, buildings it operates itself rather than leasing out triple-net, so the company keeps the upside when occupancy and rents climb. Same-store managed senior housing cash NOI rose 13.7% year over year, occupancy reached 88.2%, and rent per occupied room was up 6.6%. That momentum is why management raised full-year 2026 guidance in late July and reaffirmed it with the quarter: normalized FFO growth of roughly 7% and normalized AFFO growth of about 8%.

The balance sheet supports the story instead of threatening it. Net debt to adjusted EBITDA sits at 4.61 times, down from 5.04 times in the first quarter and below the company's longstanding 5.0 times target, and Moody's upgraded Sabra's senior notes to Baa3 investment grade last September. The company has also started putting that firepower to work, $599 million of investments this year at a 7.5% initial cash yield, including $274 million in the quarter at 8.1%, with more than $1 billion in pipeline behind it, almost all of it managed senior housing. It is even harvesting value from the old messy corner of the portfolio: Sabra reset its triple-net lease with Avamere to $48 million a year in fixed cash rent, retroactive to February, and holds letters of intent to re-tenant all 26 of those properties.

Here is the caveat an income investor has to keep honest. An analyst target is an echo of expected cash flow, not cash flow. Sabra funds growth partly by selling stock — 21.4 million shares sat under forward-sale agreements at a $19.24 weighted-average price — and fresh deals at 7.5% to 8.1% are only roughly in line with what new equity costs. The accretion is meant to come from growth — the occupancy upside it buys at about 80%, rents that are rising as leasing tightens — not from the initial yield. Judge the reinvestment by whether normalized AFFO per share keeps compounding next year, not by the deal headlines.

Three things could break the current case. First, a 75% payout is healthy, not a fortress: a stumble in senior-housing operations hits dividend headroom directly. Second, labor is the sector's swing factor, and expense per occupied room rose 4.1% in the quarter — slower than the 6.6% rent growth for now, but wage pressure is the classic way this operating leverage flips. Third, management is still consolidating the old skilled-nursing book and exiting its behavioral health business; each transition is execution risk until it closes.

For a diversified income portfolio, Sabra occupies a defined slot: a higher-yield healthcare position whose dividend is finally covered by a growing cash engine, with the balance sheet to reinvest while it pays. If you own it, the analyst raises are confirmation that the income you bank has gotten safer — not a reason to trade. If you are adding, the discipline is the same as ever: buy income you understand when the coverage is verifiable and the reinvestment math is on your side. What to watch is not a price target. It is normalized AFFO against the $0.30 quarterly dividend, and managed-housing occupancy, quarter by quarter. As long as cover holds near 1.3 times and occupancy keeps climbing, the 5.8% yield does its job whether the shares sit near $20 or at $25.